Aisheng Medical Completes Angel Round Financing to Advance Clinical Development of Small-Diameter Artificial Blood Vessels

May 27, 2025 18:56 CST Updated 18:56

AERSUN

High-end Implantable Medical Device Product Developer

SIYU Annual Event Review:The First Global Ophthalmology Conference | The First Global Orthopedics Conference | The First Global Cardiovascular Conference

Coming Soon:

June 12, 2025, The First Global Medical Aesthetics Technology Conference

July 17, 2025, The 2nd Global Medical Technology Conference

September 4-5, 2025, The 3rd Global Surgical Robotics Conference

Recently,AERSUN (Guangzhou) Biotechnology Co., Ltd.(hereinafter referred to as "AERSUN") announced the completionAngel Round FinancingThis round of financing was exclusively invested by Daotong Investment. The funds will mainly be used for the clinical advancement of small-caliber artificial blood vessels and the development of extended applications of core technologies.

# AboutAERSUN

AERSUNEstablished in 2023, headquartered in Guangzhou, it is a company focused on the development, production, and sales of high-end implantable medical device products. The company has professional R&D and manufacturing capabilities in the field of tissue repair and reconstruction, andWuhan University of TechnologyAnd has established in-depth cooperative relationships with clinical medical experts in China, dedicated to promoting the integration of medicine and engineering, and打通产学研医产业链条.

The core product of AERSUN isSmall-Caliber Artificial Blood Vessel. This product is developed using the company's proprietary technology to address pain points in clinical applications. The company has built a Class 10,000 GMP workshop and advanced laboratories in the ZHONGCHUANG Health Industry Park in Jiangxia District, Wuhan, forming capabilities in research and development, production, and testing, while also promoting clinical trials for small-diameter artificial blood vessels. The artificial blood vessel market has long been monopolized by imported products, and AERSUN’s products are expected toConstruction of Vascular Access for Hemodialysis, Coronary Artery BypassProvide higher-quality solutions in scenarios such as...

Recent Developments

April 29, 2025,AERSUNSuccessfully completedThe FirstChinese-Made Ready-to-Use Artificial Blood VesselsTheFirst Patient Clinical Trial Implantation。

The characteristics of this artificial blood vessel areReady-to-wear Design, allowing puncture dialysis within three days after surgery, significantly shortening the waiting time for patients to start dialysis. Compared with traditional artificial blood vessels, which usually require 4-8 weeks for swelling to subside before dialysis can be performed, AERSUN's product shows significant advantages in long-term patency, tolerance to repeated punctures, and ease of surgical suturing.

Welcome companies to actively participate in the conference organized by SIYU ↓

June 12, 2025, The First Global Medical Aesthetics Technology Conference

July 17, 2025, The 2nd Global Medical Technology Conference

September 4-5, 2025, The 3rd Global Surgical Robotics Conference